The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed | Alive

Total Raised




Last Raised

$30M | 13 yrs ago

About Atritech

Atritech has developed the WATCHMAN, an implantable device designed to capture clots that may form in the left atrial appendage of patients with atrial fibrillation, thereby aiming to reduce the risk of stroke and eliminating the need for long-term use of blood thinning medications.

Atritech Headquarter Location

3750 Annapolis Lane Suite 105

Plymouth, Minnesota, 55447,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Atritech Patents

Atritech has filed 53 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac arrhythmia
  • Cardiac electrophysiology
patents chart

Application Date

Grant Date


Related Topics




Cardiac anatomy, Cardiac arrhythmia, Cardiac surgery, Cardiology, Cardiac electrophysiology


Application Date


Grant Date



Related Topics

Cardiac anatomy, Cardiac arrhythmia, Cardiac surgery, Cardiology, Cardiac electrophysiology



Latest Atritech News

Watching the Watchman (again)

May 18, 2011

Paul Pisklak Cardiac Surgery , Cardiology We last reported on the Watchman left atrial appendage device back  in 2009. Since then, Minnesota based AtriTech has been acquired by Boston Scientific, and there is new data about its use as an alternative to warfarin. To review,  the Watchman is a device that is placed in the left atrium to exclude the left atrial appendage, where a thrombus is likely to form in a patient with atrial fibrillation, thus reducing the potential for a stroke. The device is implanted in the cath lab with conscious sedation ( see animation ). Previous studies have confirmed the non-inferiority of this device to warfrain, and the latest data shows its utility in patients who have contraindications to warfarin. Twenty-four of these patients were implanted with the Watchman device and received aspirin and Plavix, and no cerebrovascular events or device dislodgements were noted (follow-up time averaged 4.2 months). There was one case of a device-related thrombus that resolved with heparin therapy. Although larger studies and more follow-up time is needed, this device seems to be an option for people who are unable to take warfarin. The Watchman remains in investigational status in the United States at this time.

Atritech Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Atritech Rank

  • When was Atritech founded?

    Atritech was founded in 2000.

  • Where is Atritech's headquarters?

    Atritech's headquarters is located at 3750 Annapolis Lane, Plymouth.

  • What is Atritech's latest funding round?

    Atritech's latest funding round is Unattributed.

  • How much did Atritech raise?

    Atritech raised a total of $91.82M.

  • Who are the investors of Atritech?

    Investors of Atritech include Affinity Capital Management, Tullis Health Investors, Prism VentureWorks, Split Rock Partners, Vector Capital and 9 more.

  • Who are Atritech's competitors?

    Competitors of Atritech include ALung Technologies, Velico Medical, Lucina Health, Salutaris Medical Devices, Infrascan, Penumbra, VisionCare Ophthalmic Technologies, Apnex Medical, VeraLight, Concentric Medical and 23 more.

You May Also Like


MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.

Windy Hill Medical

Windy Hill Medical is a medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.


Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration


CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Salutaris Medical Devices

Salutaris Medical Devices (SalutarisMD) is a clinical-stage medical device company developing an investigational ophthalmic treatment for Wet Age-related Macular Degeneration (Wet AMD). SalutarisMD is developing a minimally invasive procedure that can be performed in an outpatient or physician office setting in approximately 15 minutes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.